SynthesisDigestive diseases and sciences2026
Does Fatty Pancreas Matter? Evaluating the Risk of Post-ERCP Pancreatitis in Patients with Pancreatic Steatosis: A Systemic Review and Meta-Analysis.
Synthesis in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPost-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) is a frequent and clinically significant complication. Pancreatic steatosis (PS), an increasingly common imaging finding associated with obesity, metabolic syndrome, and diabetes, may predispose the pancreas to injury during ERCP; however, its association with the risk of PEP remains uncertain.
aimTo systematically evaluate the association between pancreatic steatosis and the risk and severity of PEP.
methodsSystematic review and meta-analysis were conducted following PRISMA guidelines. MEDLINE, Embase, and Cochrane databases were searched through May 2025 for studies comparing PEP incidence in patients with and without PS. Pooled relative risks (RRs) were calculated using random-effects models. Subgroup analyses examined the impact of demographic factors, procedural variables, and diagnostic indications.
resultsFour studies involving 2108 patients were included. PS was associated with a significantly increased risk of PEP [Relative Risk (RR): 2.69; 95% confidence interval: 1.86-3.90; p = 0.32), with an incidence of 12% in patients with PS compared to 6% in those without. PS was also linked to higher risk of mild (RR: 2.25), moderate (RR: 4.73), and severe PEP (RR: 4.54). Compared to non-PS, patients with PS had higher prevalence of diabetes (RR: 1.41) and female sex (RR: 1.15). No significant differences in procedural variables or diagnostic indications were observed between the PS and non-PS groups.
conclusionPancreatic steatosis is associated with an increased risk and severity of PEP. Further high-quality prospective studies are warranted to validate this association and determine whether PS should be incorporated into pre-procedural risk stratification and targeted preventive strategies.
Indexed as
Identifiers
41326846What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.